Inhaled corticosteroids, bacterial load and the lung microbiome in COPD Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection Year: 2019
The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019 Year: 2019
Outcome of COPD exacerbations treated with and without oral steroids in relation to airway and systemic inflammation Source: Eur Respir J 2005; 26: Suppl. 49, 283s Year: 2005
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Inhaled budesonide suppresses airway and systemic eosinophilic inflammation in COPD. No predictive value of a prednisolone test treatment Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011
Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016
Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD Source: Eur Respir J, 50 (4) 1700451; 10.1183/13993003.00451-2017 Year: 2017
Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Inhaled corticosteroids decrease exercise-induced inflammation in patients with COPD Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease Year: 2007